144 related articles for article (PubMed ID: 31622214)
21. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
23. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
24. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
25. A place for precision medicine in bladder cancer: targeting the FGFRs.
di Martino E; Tomlinson DC; Williams SV; Knowles MA
Future Oncol; 2016 Oct; 12(19):2243-63. PubMed ID: 27381494
[TBL] [Abstract][Full Text] [Related]
26. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
27. Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.
Yang D; Ma Y; Zhao P; Ma J; He C
Biomed Pharmacother; 2019 Dec; 120():109433. PubMed ID: 31568988
[TBL] [Abstract][Full Text] [Related]
28. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.
Wu M; Chen J; Wang Y; Hu J; Liu C; Feng C; Zeng X
Oncotarget; 2015 Oct; 6(31):30887-901. PubMed ID: 26429874
[TBL] [Abstract][Full Text] [Related]
29. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
30. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
31. DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Hahn NM; Waddell J; Olbricht GR; Zheng R; Stewart JC; Knapp DW
Urol Oncol; 2013 Nov; 31(8):1761-9. PubMed ID: 22609058
[TBL] [Abstract][Full Text] [Related]
32. Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer.
Cavanaugh A; Juengst B; Sheridan K; Danella JF; Williams H
Oncotarget; 2015 Nov; 6(37):39821-38. PubMed ID: 26556859
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor and bladder cancer: a review.
Neal DE; Mellon K
Urol Int; 1992; 48(4):365-71. PubMed ID: 1357809
[TBL] [Abstract][Full Text] [Related]
34. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
36. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
[TBL] [Abstract][Full Text] [Related]
37. Targeting EGFR in bladder cancer.
Villares GJ; Zigler M; Blehm K; Bogdan C; McConkey D; Colin D; Bar-Eli M
World J Urol; 2007 Dec; 25(6):573-9. PubMed ID: 17690890
[TBL] [Abstract][Full Text] [Related]
38. Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
Mora Vidal R; Regufe da Mota S; Hayden A; Markham H; Douglas J; Packham G; Crabb SJ
Urology; 2018 Feb; 112():225.e1-225.e7. PubMed ID: 29154981
[TBL] [Abstract][Full Text] [Related]
39. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium.
Røtterud R; Fosså SD; Nesland JM
Histol Histopathol; 2007 Apr; 22(4):349-63. PubMed ID: 17290345
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?
Gazquez C; Ribal MJ; Marín-Aguilera M; Kayed H; Fernández PL; Mengual L; Alcaraz A
BJU Int; 2012 Nov; 110(9):1310-6. PubMed ID: 22416928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
